Jupiter Topco LLC Takes $7.60 Million Position in Kenvue Inc. $KVUE

Jupiter Topco LLC bought a new position in shares of Kenvue Inc. (NYSE:KVUE) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 397,673 shares of the company’s stock, valued at approximately $7,600,000.

A number of other large investors also recently modified their holdings of the company. CoreCap Advisors LLC raised its holdings in Kenvue by 64.9% during the second quarter. CoreCap Advisors LLC now owns 1,502 shares of the company’s stock worth $29,000 after buying an additional 591 shares during the last quarter. Montag A & Associates Inc. grew its holdings in shares of Kenvue by 6.3% during the first quarter. Montag A & Associates Inc. now owns 10,156 shares of the company’s stock valued at $175,000 after buying an additional 600 shares during the last quarter. Cornerstone Wealth Group LLC grew its holdings in shares of Kenvue by 5.9% during the first quarter. Cornerstone Wealth Group LLC now owns 10,810 shares of the company’s stock valued at $187,000 after buying an additional 606 shares during the last quarter. Mill Creek Capital Advisors LLC increased its position in shares of Kenvue by 0.6% during the fourth quarter. Mill Creek Capital Advisors LLC now owns 124,213 shares of the company’s stock worth $2,143,000 after acquiring an additional 701 shares in the last quarter. Finally, B & T Capital Management DBA Alpha Capital Management increased its position in shares of Kenvue by 0.3% during the fourth quarter. B & T Capital Management DBA Alpha Capital Management now owns 234,664 shares of the company’s stock worth $4,048,000 after acquiring an additional 712 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

Kenvue Stock Performance

KVUE stock opened at $19.15 on Monday. The company has a quick ratio of 0.71, a current ratio of 1.01 and a debt-to-equity ratio of 0.67. The firm has a market cap of $36.78 billion, a PE ratio of 22.01, a P/E/G ratio of 1.37 and a beta of 0.47. The business has a 50 day moving average of $19.16 and a 200-day moving average of $18.25. Kenvue Inc. has a 12-month low of $14.02 and a 12-month high of $20.82.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.31 EPS for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.01). Kenvue had a return on equity of 21.22% and a net margin of 10.76%.The business had revenue of $3.96 billion for the quarter, compared to the consensus estimate of $3.97 billion. During the same quarter last year, the business posted $0.29 earnings per share. The business’s revenue was up 3.0% compared to the same quarter last year. As a group, sell-side analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, August 26th. Stockholders of record on Wednesday, August 12th were given a dividend of $0.21 per share. The ex-dividend date of this dividend was Wednesday, August 12th. This represents a $0.84 annualized dividend and a dividend yield of 4.4%. This is a boost from Kenvue’s previous quarterly dividend of $0.21. Kenvue’s payout ratio is 96.55%.

Analysts Set New Price Targets

KVUE has been the topic of several recent research reports. Wall Street Zen cut shares of Kenvue from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Barclays boosted their price objective on Kenvue from $18.00 to $19.00 and gave the stock an “equal weight” rating in a report on Tuesday, July 21st. Weiss Ratings raised Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, June 15th. Zacks Research lowered Kenvue from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 7th. Finally, UBS Group cut their target price on Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a research report on Tuesday, August 11th. Three equities research analysts have rated the stock with a Buy rating and twelve have given a Hold rating to the company. According to MarketBeat, Kenvue presently has a consensus rating of “Hold” and a consensus target price of $19.27.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.